Search results for "INTERFERON"

showing 10 items of 963 documents

The Acute Phase Response in Sicilian Patients with Boutonneuse Fever Admitted to Hospitals in Palermo, 1992–1997

2001

Abstract Objectives : To study the modifications of some components of the acute phase response (APR) in Sicilian patients with boutonneuse fever (BF) caused by Rickettsia conorii . Methods : Sera from 500 Sicilian patients with confirmed BF were studied at the time of diagnosis and every week after treatment, and after recovery for the presence of various inflammatory mediators. Tumour necrosis factor α (TNFα), interleukin(IL)-6, IL-1α, IL-8, soluble TNF receptors (sTNF-R) and sIL-6R were assayed by commercially ELISA kits. C3, C4, factor B, C-reactive protein (CRP), fibrinogen, ceruloplasmin (Cp) and α 1 -antitrypsin (AAT) were assayed by a rate nephelometry. Results : Interferon gamma (I…

AdultMaleMicrobiology (medical)Time Factorsmedicine.medical_treatmentBoutonneuse FeverFibrinogenmedicineHumansInterferon gammaAcute-Phase ReactionAgedbiologybusiness.industryAcute-phase proteinInterleukinMiddle Agedmedicine.diseasebiology.organism_classificationAntibodies BacterialBoutonneuse feverRickettsia conoriiInfectious DiseasesCytokineItalyImmunologyCytokinesFemaleTumor necrosis factor alphaRickettsia conoriibusinessAcute-Phase Proteinsmedicine.drugJournal of Infection
researchProduct

LIODetect®TB-ST: Evaluation of novel blood test for a rapid diagnosis of active pulmonary and extra-pulmonary tuberculosis in IGRA confirmed patients

2021

Abstract Because of the current limits of immunological tests in the diagnosis of tuberculosis there is a need to identify new and rapid tests that can be carried out on a large scale in endemic countries and useful in the identification of infected subjects, but also able to discriminate those with latent infection from subjects with active. We have taken into consideration and analysed the LIODetect®TB-ST Tuberculosis Rapid Test, a membrane test for the qualitative detection of specific IgG, IgA, and IgM antibodies against Mycobacterium tuberculosis, performed on serum, plasma, or whole blood.85 samples positive to QuantiFERON TB-GOLD PLUS test were processed using this test and the resul…

AdultMaleMicrobiology (medical)TuberculosisIgm antibodyImmunologyDiseaseSensitivity and SpecificityMicrobiologyQuantiferon TB GoldQuantiFERONMycobacterium tuberculosisExtra pulmonary tuberculosisPLUSHumansTuberculosisMedicineBlood testTuberculosis PulmonaryIFN-γHematologic Testsbiologymedicine.diagnostic_testbusiness.industrySpecific iggMycobacterium tuberculosisMiddle Agedbiology.organism_classificationmedicine.diseaseAntibodies BacterialInfectious DiseasesImmunologyFemalebusinessLIODetect®TB-STInterferon-gamma Release Tests
researchProduct

Response-adjusted α-interferon therapy for chronic hepatitis C in HIV-infected patients

2000

Abstract In patients with chronic hepatitis C and HIV infection, responsiveness to the standard schedule of α-interferon (IFN) is unsatisfactory. To quantify the effectiveness of tailoring IFN dosage according to HCV viral load under treatment, we enrolled 41 patients (M/F 32/9) chronically coinfected by HCV and HIV with chronic liver disease. All were former i.v. drug addicts, with a mean age of 32±4 years, and had clinical and histological evidence of chronic hepatitis (10% with cirrhosis). The CDC stage was A1 in five, A2 in 14, A3 in eight, B2 in eight, B3 in three and C3 in three. Twenty four patients were on triple therapy with protease inhibitors, 11 were on two-drug anti-HIV regimen…

AdultMaleMicrobiology (medical)medicine.medical_specialtyCirrhosisSubstance-Related DisordersAlpha interferonHIV InfectionsHepacivirusChronic liver diseaseAntiviral AgentsGastroenterologyLiver diseaseInternal medicinemedicineHumansPharmacology (medical)Interferon alfabusiness.industryHIVInterferon-alphavirus diseasesGeneral MedicineHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseCD4 Lymphocyte CountTreatment OutcomeInfectious DiseasesImmunologyPatient ComplianceFemaleViral diseasebusinessViral loadmedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

2022

Background and ObjectivesSeveral studies have assessed risk factors associated with the severity of COVID-19 outcomes in people with multiple sclerosis (PwMS). The potential role of disease-modifying therapies (DMTs) and demographic and clinical factors on the risk of acquiring SARS-CoV-2 infection has not been evaluated so far. The objective of this study was to assess risk factors of contracting SARS-CoV-2 infection in PwMS by using data collected in the Italian MS Register (IMSR).MethodsA case-control (1:2) study was set up. Cases included PwMS with a confirmed diagnosis of COVID-19, and controls included PwMS without a confirmed diagnosis of COVID-19. Both groups were propensity score–m…

AdultMaleMultiple SclerosisTime Factors41Dimethyl FumarateSex FactorRelapsing-RemittingSeverity of Illness IndexArticleImmunosuppressive AgentSex FactorsMultiple Sclerosis Relapsing-RemittingRisk FactorsMultiple SclerosiOdds RatioHumansAge Factor36053g COVID-19Fingolimod HydrochlorideSARS-CoV-2NatalizumabRisk FactorAge FactorsCOVID-19Glatiramer AcetateInterferon-betaMiddle AgedMultiple Sclerosis Chronic Progressive323Chronic ProgressiveNeurologyItalyCase-Control StudiesAdult; Age Factors; COVID-19; Case-Control Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time FactorsFemaleNeurology (clinical)Case-Control StudieImmunosuppressive AgentsHuman
researchProduct

TNFalpha, IFNgamma and IL-10 gene polymorphisms in a sample of Sicilian patients with coeliac disease.

2005

Coeliac disease is associated with DQ2 and DQ8 alleles, but other genes also confer an additional genetic risk.Defining whether the genetic profiles of interleukin-10, tumour necrosis factor alpha and interferon gamma are associated with an increased coeliac disease risk.The functionally gene polymorphisms of tumour necrosis factor alpha (-308G/A), interferon gamma (+874T/A) and interleukin-10 (-1082G/A) were typed using sequence specific primer-polymerase chain reaction in 110 Sicilian coeliac disease patients and in 220 Sicilian healthy controls.No differences in genotype frequencies of interleukin-10 polymorphisms were found between coeliac disease patients and healthy controls. A signif…

AdultMaleNecrosisAdolescentGenotypeCoeliac diseaseInterferon-gammaGene FrequencymedicineHumansGenetic Predisposition to DiseaseAlleleChildGeneSicilyPolymorphism GeneticHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologynutritional and metabolic diseasesInfantGluten intoleranceMiddle Agedmedicine.diseaseGenotype frequencyInterleukin-10Interleukin 10Celiac DiseaseCase-Control StudiesChild PreschoolImmunologyTumor necrosis factor alphaFemalemedicine.symptombusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.

1998

Acute infection with hepatitis C virus (HCV) develops into a chronic hepatitis in about 50-70% of patients. Treatment of these patients with interferon-alpha (IFN-alpha) results in a sustained long-term response in only 15-20% but causes numerous unwanted side-effects in a higher percentage of patients. The aim of our study was to define host or viral parameters that would allow identification of responders and non-responders to IFN-alpha prior to the onset of treatment. We studied a group of 87 patients suffering from chronic hepatitis C who were treated with IFN-alpha. After long-term follow-up, 18 patients (21%) showed a sustained response to IFN-alpha therapy (normalization of serum tra…

AdultMaleNecrosisGenotypeHepatitis C virusAlpha interferonInflammationHepacivirusmedicine.disease_causeAntiviral AgentsFibrosisVirologyGenotypemedicineHumansViremiaHepatologymedicine.diagnostic_testbusiness.industryTumor Necrosis Factor-alphaInterferon-alphaHLA-DR AntigensHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseInfectious DiseasesTreatment OutcomeLiver biopsyImmunologyRNA ViralFemalemedicine.symptombusinessViral hepatitisFollow-Up StudiesJournal of viral hepatitis
researchProduct

Brain atrophy and lesion load in a large population of patients with multiple sclerosis

2005

Objective: To measure white matter (WM) and gray matter (GM) atrophy and lesion load in a large population of patients with multiple sclerosis (MS) using a fully automated, operator-independent, multiparametric segmentation method. Methods: The study population consisted of 597 patients with MS and 104 control subjects. The MRI parameters were abnormal WM fraction (AWM-f), global WM-f (gWM-f), and GM fraction (GM-f). Results: Significant differences between patients with MS and control subjects included higher AWM-f and reduced gWM-f and GM-f. MRI data showed significant differences between patients with relapsing-remitting and secondary progressive forms of MS. Significant correlations bet…

AdultMalePathologymedicine.medical_specialtyAdolescentBrain mappingNerve Fibers MyelinatedCentral nervous system diseaseWhite matterMultiple sclerosisAtrophySex FactorsPredictive Value of TestsNeural PathwaysmedicineHumansAge of OnsetMultiple Sclerosis/physiopathologyAgedCross-Sectional StudieBrain MappingExpanded Disability Status Scalemedicine.diagnostic_testBrain/physiopathologybusiness.industryMultiple sclerosisBrainMagnetic resonance imagingInterferon-betaMiddle Agedmedicine.diseasePrognosislesion loadMagnetic Resonance ImagingMultiple Sclerosis/diagnosimedicine.anatomical_structureCross-Sectional Studiesmultiple sclerosiLinear ModelsDisease ProgressionEducational StatusFemaleNeurology (clinical)Age of onsetAtrophybusinessMultiple Sclerosis/complicationbrain atrophyMRI
researchProduct

Increased expression of interleukin-32 in the inflamed ileum of ankylosing spondylitis patients

2012

Objective. To study the mRNA expression and protein tissue distribution of IL-32 in ileal biopsy specimens from patients with AS. Methods. Quantitative gene expression analysis, by real-time PCR, of IL-32, IL-1b, IL-10, TNF-a and IFN-g was performed on ileal biopsies of 15 AS and 15 Crohn’s disease (CD) patients and 10 healthy subjects (HSs). IL-32 tissue distribution was evaluated by immunohistochemistry. The effect of IL-32 on the production of IL-10 by intestinal epithelial cell lines was also evaluated. Results. In the ileal specimens of patients with AS and intestinal chronic inflammation, significant up-regulation of IL-32 at both the mRNA and protein levels was found as compared with…

AdultMalePathologymedicine.medical_specialtyAdolescentmedicine.medical_treatmentInterleukin-1betaInflammationInterferon-gammaYoung AdultCrohn DiseaseRheumatologyIleumBiopsyintestinal inflammationmedicineHumansSpondylitis AnkylosingPharmacology (medical)IleitisRNA MessengerCrohn's diseasemedicine.diagnostic_testTumor Necrosis Factor-alphabusiness.industryInterleukinsMacrophagesIL-32 ankylosing spondylitis IL-10 intestinal inflammationInterleukinEpithelial CellsIleitisMiddle AgedHCT116 Cellsmedicine.diseaseImmunity InnateInterleukin-10Settore MED/16 - ReumatologiaInterleukin 10Interleukin 32ankylosing spondylitiCytokineCase-Control StudiesImmunologyIL-32IL-10Femalemedicine.symptombusiness
researchProduct

Morphometric Study of the Bone Marrow in Polycythemia Vera Following Interferon-Alpha Therapy

1993

Bone marrow cellularity and extent of fibrotic change were determined in nineteen patients with polycythemia vera, treated with interferon-alpha (IFN) for 1 year. The cellularity was evaluated with an interactive semiautomatic method using Leitz TAS plus microscope: in particular, number and size of megakaryocytes were evaluated after immunostaining with Y2/51 (CD 61); reticulin content was studied by light microscope with a semiquantitative method. Before IFN therapy mean cellularity was 80.5% (+/- 13.7). After 6 and 12 months mean cellularity was 75.4% and 68.4% respectively. Six months after cessation of IFN therapy the cellularity was 69.1%. A decrease of the number, density and morphom…

AdultMalePathologymedicine.medical_specialtyAlpha interferonCell CountPathology and Forensic MedicinePolycythemia veraBone MarrowFibrosishemic and lymphatic diseasesmedicineHumansMyelofibrosisPolycythemia VeraAgedAged 80 and overbusiness.industryInterferon-alphaCell BiologyMiddle Agedmedicine.diseaseBone marrow cellularitymedicine.anatomical_structurePrimary MyelofibrosisMarrow fibrosisFemaleBone marrowbusinessMegakaryocytesImmunostainingPathology - Research and Practice
researchProduct

Safety of potential breast milk exposure to IFN-β or glatiramer acetate

2019

ObjectiveTo determine whether potential breast milk exposure to interferon-beta (IFN-β) or glatiramer acetate (GA) is safe for the infant.MethodsWe identified 74 infants born to 69 women with MS who breastfed under IFN-β (n = 39), GA (n = 34), or both (n = 1). Women had been enrolled into the German Multiple Sclerosis and Pregnancy Registry during pregnancy. Data were obtained from standardized, telephone-administered questionnaires completed by the mother during pregnancy and at 1, 3, 6, and 12 months postpartum and the infant's take-home medical record.ResultsThe median duration of exposed breastfeeding was 8.5 months (wide interquartile range: 4.9–12.7 months). Physical growth curves dur…

AdultMalePediatricsmedicine.medical_specialtyMultiple Sclerosis41BreastfeedingBreast milkArticleChild DevelopmentPregnancyInterquartile rangemedicineHumansImmunologic FactorsRegistriesGlatiramer acetatePregnancyMilk Humanbusiness.industryPostpartum PeriodInfantGlatiramer AcetateInterferon-betamedicine.disease54Pregnancy ComplicationsBreast FeedingNeurologyFemaleMedian bodyNeurology (clinical)businessBreast feedingPostpartum periodmedicine.drugNeurology - Neuroimmunology Neuroinflammation
researchProduct